Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CSTL | CLUSTER | bearish | 4/10 | Multiple C-suite insiders at Castle Biosciences sold shares totaling $195K in a cluster over the past week. The CEO, COO | Sep 4, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined $515K in open-market shares over a week, represen | Sep 4, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/General Counsel Paul Mahon sold a combined ~$5.8M in open-market shares over two days, pri | Sep 4, 2026 |
| SYRE | CLUSTER | bearish | 5/10 | CEO Cameron Turtle and CFO Scott Burrows sold a combined $810K in open-market sales on September 1, 2026. These sales fo | Sep 3, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders sold a combined $4.01M in stock over a week, including a Director's $3.27M sale. The t | Sep 3, 2026 |
| ARTV | CLUSTER | bearish | 4/10 | Four Artiva insiders, including CEO Fred Aslan, sold a total of $912K in shares on September 3, 2026, all at $11.16. The | Sep 3, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two senior Alkermes executives (EVP/CLO and EVP R&D/CMO) sold a combined $521K in open-market shares over a 3-day window | Sep 3, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined 88.5K shares for ~$619K in open-market sales over | Sep 3, 2026 |
| IRON | CLUSTER | bearish | 5/10 | Director Kevin Bitterman sold ~$4.4M of IRON stock in a concentrated 7-day cluster, while COO Jonathan Yu sold $731K. Th | Sep 3, 2026 |
| GILD | CLUSTER | neutral | 2/10 | GILD insiders, including Chairman & CEO Daniel O'Day and Director Anthony Welters, sold a total of ~$921K in open-market | Sep 3, 2026 |
| OCUL | CLUSTER | neutral | 4/10 | Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief | Sep 3, 2026 |
| CAMP | CLUSTER | neutral | 3/10 | Camp4 Therapeutics Corp (CAMP) insider trading cluster shows a mixed pattern: Director Andrew Schwab sold 400,000 shares | Sep 2, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Two C-suite insiders at Nurix Therapeutics (NRIX) — Chief Scientific Officer Gwenn Hansen and Chief Legal Officer Christ | Sep 2, 2026 |
| GNLX | CLUSTER | bearish | 5/10 | Three top executives at GENELUX Corp — the CEO, CSO, and CTO — sold a combined $147K in open-market sales on August 31, | Sep 2, 2026 |
| JAZZ | CLUSTER | bearish | 4/10 | A cluster of insider selling at Jazz Pharmaceuticals totals $6.01M in open-market sales over a 7-day window. The largest | Sep 2, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences (CEO, COO, CCO) sold a total of $373K in open-market transactions over a on | Sep 2, 2026 |
| OMER | CLUSTER | neutral | 2/10 | Three OMER insiders (VP/General Counsel, Director, VP Finance) sold a combined ~$578K in open-market shares over a week, | Sep 2, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Three C-suite insiders at Castle Biosciences (CEO, CCO, COO) sold shares totaling $878K over a week. The CEO's transacti | Sep 2, 2026 |
| FENC | CLUSTER | neutral | 4/10 | Two C-suite insiders at Fennec Pharmaceuticals (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day w | Sep 2, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Three CYTK insiders (CEO, EVP, Director) sold a total of $1.59M in open-market shares over a 7-day window, primarily fro | Sep 2, 2026 |
| QNRX | CLUSTER | mixed | 6/10 | Three insiders at Quoin Pharmaceuticals (CEO, CFO, and a Director) made open-market purchases totaling $180K at $4.88/sh | Sep 1, 2026 |
| ROIV | CLUSTER | neutral | 3/10 | Two senior Roivant executives (President & CIO Mayukh Sukhatme and President & Immunovant CEO Eric Venker) sold a combin | Sep 1, 2026 |
| ORKA | CLUSTER | bearish | 4/10 | Oruka Therapeutics CEO Lawrence Klein and COO Laura Sandler sold a combined $5.94M in open-market stock on September 1, | Sep 1, 2026 |
| XERS | CLUSTER | neutral | 3/10 | Three Xeris Biopharma insiders (McCulloch, Hecht, Pieper) sold a combined $311K in open-market shares on September 1, 20 | Sep 1, 2026 |
| ANIP | CLUSTER | neutral | 3/10 | Two top ANIP executives—CEO Nikhil Lalwani and CFO Stephen Carey—collectively sold $609K in open-market shares within a | Sep 1, 2026 |
| MEDP | CLUSTER | neutral | 2/10 | Three Medpace insiders (CEO, CFO, Director) sold a combined $4.91M in open-market sales over a 7-day window. However, th | Sep 1, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined ~$1.44M of TRDA shares over five days, representi | Sep 1, 2026 |
| FENC | CLUSTER | neutral | 4/10 | Two Fennec Pharmaceuticals executives (CFO and CMO) sold a combined $1.03M in open-market shares over a 5-day window, re | Aug 31, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two MPM BioVentures funds (10% owners) sold a combined $383K in TRDA shares over a 7-day window, representing ~0.14% of | Aug 31, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | CEO Robert Blum and EVP Andrew Callos each exercised and immediately sold vested stock options on the same day, totaling | Aug 31, 2026 |